FINWIRES · TerminalLIVE
FINWIRES

$CADL

2 stories mentioning CADLUpdated just now

Every FINWIRES story that references CADL, newest first.

What are analysts saying about CADL?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on CADL?

Insider Trading

Candel Therapeutics Insider Sold Shares Worth $3,160,783, According to a Recent SEC Filing

Paul Peter Tak, Director, Chief Executive Officer, on September 10, 2026, sold 280,245 shares in Candel Therapeutics (CADL) for $3,160,783. Following the Form 4 filing with the SEC, Tak has control over a total of 113,321 common shares of the company, with 113,321 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1841387/000187390526000002/xslF345X05/ownership.xml

$CADL
Research

Stifel Nicolaus Initiates Coverage on Candel Therapeutics With Buy Rating, $22 Price Target

$CADL

Track with the FINWIRES app suite

FolioX
FolioX
Track CADL in your portfolio
WheelAI
WheelAI
Analyze CADL options with the wheel strategy
StockInsider
StockInsider
See market sentiment on CADL